Decision-makers need to know the extent to which a drug does more good than harm. Under controlled conditions, such as in RCTs, this is termed efficacy while in real life conditions this is termed effectiveness. It is critical for regulators to understand the efficacy without any confounding factors and most trial data at launch is focussed on providing such information.
Paradigm 2
• In this paradigm, the "ideal" drug's effect is thought to be distorted by real-life factors: the "behaviour" of carers and patients' adherence to treatment
• To narrow the EEG, it has been suggested to bring up real-life care to : promotion of knowledge dissemination, medical guidelines, adherence-enhancement strategies, etc. 
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Objectives
Work Package 2 of the IMI GetReal consortium has conducted a review of the origins of the concept of EEG:
1. On which historical background has it emerged? 2. How has the EEG been conceptualized and which solutions have been suggested to narrow the gap?
The purpose of the review was to inform development of a framework to identify which contextual factors have a meaningful impact on the effect of a drug
• In this paradigm, the EEG is understood as an issue of measure: different study designs (RCTs vs. effectiveness studies) to assess the impact of drugs, provide different results
• On one hand, the underlying assumption of the concept of evidence-based medicine and hierarchy of evidence is that: efficacy is the real effect of the drug whereas effectiveness is a distorted one, derived from "biased" real-life observational studies
• On the other hand, the concept of "pragmatism" suggests that RCTs are lacking external validity and generalizability
• It has been suggested that RCTs can be modified to include elements of real world data Paradigm 1
• Another paradigm is emerging: the difference between the effects of a drug as measured in an experimental setting or in routine practice is the result of the interaction of multiple "real-life" characteristics on the biological effect of the drug
Paradigm 3
The GetReal consortium aims to improve the efficiency of the medicine development process by better incorporating estimates of relative effectiveness into drug development and to enrich decision-making by regulatory authorities and HTA bodies. This work has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement n° [115546] , resources of which are composed of financial contribution from the European Union (FP7/2007-2013) and EFPIA companies' in kind contribution.
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Results
• EEG is a concept that can be traced back to 1995 • The literature on the EEG can be classified into three paradigms: (i) the impact of the methodology used in assessment of the drug's effects , (ii) the impact of the patient and the physician's behaviour, and (iii) the interaction between the drug and contextual factors • The key drivers that cause this gap are still to be identified Major publications on the concepts of "Evidence-based Medicine" and "hierarchy of evidence" (1996) 
